Acrigen Biosciences secures seed funding

By The Science Advisory Board staff writers

September 28, 2021 -- Biotechnology firm Acrigen Biosciences has secured seed funding that it plans to use to further develop its pipeline of gene editing technology and genetic medicines.

The financing round was led by Red Tree Venture Capital with participation from Alexandria Venture Investments, the Berkeley Catalyst Fund, and Dolby Family Ventures. Red Tree Venture Capital Founder Heath Lukatch, PhD, will join Acrigen's board.

Acrigen is a spinoff from the gene editing laboratories at the University of California, Berkeley. The company recently tapped Trevor Collingwood, PhD, as its chief technology officer.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.